Introduction
Herpes simplex virus (HSV) is an enveloped doublestranded DNA virus. The mature virion consists of several components: an external envelope containing different glycoproteins involved in different functions, among which the first steps are binding and entry into the host cell; an amorphous layer known as the tegument, containing some 20 different proteins with structural and regulatory roles; and an icosadeltahedral capsid containing a toroidal double-stranded DNA. Of the 84 viral genes encoded by the 152 kb genome ( Figure  1 ), classified according to whether their expression is essential for viral replication in tissue culture, the nonessential genes often encode functions that are important for specific virus-host interactions in vivo, such as immune evasion, replication in nondividing cells and shutdown of host protein synthesis. These nonessential genes can be deleted to generate gene therapy vectors, allowing the insertion of exogenous genetic material. 1 Different aspects of HSV biology render this virus attractive for the designing of gene therapy vectors:
HSV displays a broad host cell range and its cellular receptors, heparan sulfate (HS), herpesvirus entry mediator (HVEM), and nectin-1 and 2, are widely expressed on the cell surface of numerous cell types. HSV is highly infectious. Nondividing cells may be efficiently infected and transduced by HSV. Almost half of the 84 known viral genes are nonessential for growth in tissue culture and then may be deleted to create genomic space for exogenous transgenes and to delete functions essential for virulence and toxicity in vivo. Recombinant HSV vectors can be easily produced to high titer and purity without wild-type (wt) contaminants. The latent behavior of the virus may be exploited for stable long-term expression of therapeutic transgenes in neurons.
Deletion of some nonessential genes results in viruses that retain the ability to replicate in vitro, but are compromised in vivo, in a context-dependent manner. 2, 3 Among the limitations to the use of HSV is the fact that wt virus is highly pathogenic and cerebral injection causes fatal encephalitis. Toxic and/or pathogenic properties of the virus must, therefore, be disabled prior to its use as a gene delivery vector.
Use of nonreplicating viruses or nonviral systems as vectors can limit the maximum achievable efficiency of gene transfer. In contrast, use of replicating vectors to allow replication of genes delivered initially to a small number of cells and their subsequent transfer to neighboring cells, as infection spreads, can significantly increase the efficacy of gene delivery. [4] [5] [6] Replicating viral vectors raise serious safety concerns relating to the inherent mutagenicity of animal viruses. Prior to a replicating vector being tested in the clinic, several safety considerations should be addressed. There are different points that should be kept in mind while constructing an attenuated vector.
The replicating vector could be pathogenic for the treated patient or damage normal tissue. If this is the case, the severity of the illness has to be evaluated and there should be the search for an effective treatment. The replicating vector could undergo mutation or recombination in vivo to a new strain potentially more harmful than the replicating vector or its wt counterpart.
The replicating vector or a more pathogenic mutant could spread from the patient to other human subjects. The replicating vector or a more pathogenic mutant could cause harm to a developing embryo or to a fetus.
Several genes involved in HSV replication, virulence and immune evasion, nonessential for the viral life cycle in vivo, have been identified. These genes are usually involved in multiple interactions with cellular proteins, which optimize the ability of the virus to grow within cells. Understanding such interactions has permitted the deletion/modification of these genes, alone or in combination, to create HSV mutants with a reduced ability to replicate in normal quiescent cells, but that can replicate in tumor or dividing cells. These attenuated viruses harbor further modification so they also serve as therapeutic gene delivery vehicles. 3, 7 Which gene should be deleted in a live attenuated HSV vector? Many HSV-1 genes that are nonessential in culture alter virulence in animal models. Fewer HSV-2 genes have been studied, and there are almost certainly type-specific effects. Among these genes, the ones encoding thymidine kinase (TK), ribonucleotide reductase (RR), the virion-host shut off (vhs) and the ICP34.5 proteins have been extensively studied.
TK is involved in optimizing nucleic acid metabolism for virus growth and is necessary for efficient replication in neurons. RR is necessary for the conversion of rNTPs to dNTPs in neurons, which are otherwise lacking but necessary for the synthesis of new viral DNA during virus replication. The vhs function of HSV causes rapid destabilization of host RNAs and translational arrest. Vhs also destabilizes viral messages, resulting in overaccumulation of immediate-early and early genes during lytic infection. The ICP34.5 neurovirulence factor has been found to be essential for HSV pathogenicity. It appears to provide multiple functions to the virus life cycle, one of which is to block the arrest in translation, which usually occurs in virus-infected cells as an antiviral response preventing virus replication. This effect is mediated through the cellular PKR kinase, which phosphorylates the translation initiation factor eIF2a, thereby stopping translation. ICP34.5 recruits protein phosphatase 1a to rephosphorylate eIF2a, allowing protein translation and continued virus replication. Tumor cells often display an impaired PKR pathway and/or elevated levels of eIF2a that allow replication of ICP34.5-deleted viruses, as the inactivation of the PKR response is less critical in this contest. Secondly, ICP34.5 seems to be involved in allowing new virions to become packaged and leave infected cells in a cell type-specific fashion. Consequently, in nonpermissive cells in the absence of ICP34.5, the nucleocapsids are retained in the nucleus and a productive infection cannot ensue.
When constructing a recombinant virus for use as an attenuated vaccine or vector, it is possible to overattenuate the virus, which could possibly negate its value. To minimize this possibility, a gradation of additional deletions has to be introduced and evaluated for eventual overattenuation.
Attenuated HSV vectors have been tested as live viral vaccines, as oncolytic viruses, and as gene therapy vectors to deliver transgenes to the nervous system.
Live viral anti-HSV vaccine
Live attenuated viral vaccines have many clear advantages. They provide a vehicle for complete presentation of all viral antigens to the host's immune system, stimulating both humoral and cell-mediated immune responses. They can be efficiently propagated with ease and are therefore extremely cost-effective vaccines. Live attenuated viruses have also been successful at combating myriad human viral diseases. The concerns surrounding the development of a live viral vaccine for HSV are mainly safety issues revolving around the potential for reactivation from latency, recombination with wt virus, and the oncogenic potential of viral DNA. [8] [9] [10] [11] The first attenuated HSV virus to be constructed and analyzed as a viral vaccine in humans was the NV1020 (formerly R7020) strain. 12, 13 This virus, based on HSV-1 strain F, has a portion of the unique short region of the viral genome encoding glycoproteins G, D, I and E, replaced by the homologous region from HSV-2, and possesses one copy of ICP4. This virus was very strongly attenuated in rodents and primates. In a dose-escalation study, local reactions were noted in HSV-1-infected persons. A dose-dependent induction of antibodies occurred in HSV-seronegative subjects, but the development of this mutant has been stopped since it resulted too overattenuated, and it was consequently poorly immunogenic.
The goal to construct a safe, less attenuated vaccine candidate, led to the construction of the RAV 9395 mutant. 8 When used as a live viral vaccine in a guinea pig model of HSV infection, it was shown to be protective, and also demonstrated that the immunologic answer depended on the route of administration of the virus. RAV 9395 is based on HSV-2 strain G, which Figure 1 Map of HSV-1 genome. A schematic representation of the positions of the genes encoding proteins involved in virus replication, regulation, in viral formation and assembly, and in virion structural proteins is depicted. Genes that are modified or deleted to achieve viral attenuation are indicated.
Replication-competent HSV vectors R Argnani et al S171 carries deletions in the UL55 and UL56 genes, encoding proteins with unknown functions, the deletion of which causes attenuation, and deletion in both copies of the g34.5 gene. Concomitant with this deletion, both copies of the open reading frame (ORF) P have also been deleted. The tk gene was left intact and functional, conferring acyclovir sensitivity to the recombinant virus.
Mutations in tk, especially for HSV-2, do not attenuate the virus sufficiently for human vaccines.
14 Other attenuated HSV-1 and HSV-2 viruses with single deletion in vhs or in RR, respectively, 15, 16 were shown to determine a protective immunity when tested in animal models, but they still are too neurovirulent to be used for human trials.
Oncolytic HSV attenuated viruses
A replicating vector for cancer therapy should be derived from viruses that are naturally endemic to the human population. The optimal strategy might be to develop a replicating vector from a highly prevalent but weakly pathogenic human virus. Reversion to wt would then be of no serious risk to the patient or to the population.
Construction of oncolytic viruses that cannot only target cancer cells but can also retain their ability to infect, usurp host replication machinery, then release newly made progeny to infect other transformed cells after lysing and killing the host cell, has become a major area of therapeutic cancer research. There are some characteristics that an ideal replication-competent, oncolytic virus should possess above and beyond those viruses that function simply as delivery vectors: (i) be easy to engineer and to produce in large quantities; (ii) selectivity to neoplastic cell alone; (iii) minimal toxicity to normal tissue; (iv) show proliferation within and systematic killing of tumor tissue, which itself may be rapidly propagating; (v) ability to disseminate throughout the tumor mass and possibly to sites of invasion distant from the initial inoculation site; (vi) carry low or bearable toxicity; (vii) genomically stable, thus avoiding the generation of toxic, undesirable mutants that could pose a danger; (viii) incorporate a 'fail-safe' mechanism for inactivation; (ix) absence of potential spread to the general population; and (x) enduring efficacy despite the prospect of encountering a mounting immune response to replicating viruses. [2] [3] [4] [5] [6] [7] [17] [18] [19] [20] [21] So far, several oncolytic HSV vectors have been developed (Table 1 ). The first generation of these vectors contained mutations in a single gene that restricted their replication to dividing cells. Three such HSV-1 mutants were constructed: (1) dlsptk containing a deletion in the tk gene; (2) hrR3 containing an insertion of the Escherichia coli lac-Z gene in the early gene UL39, encoding the large subunit of the viral RR (ICP6); (3) R3616 containing 1 kb deletions in both copies of the g34.5 gene, encoding the neurovirulence factor ICP34.5.
TK mutants are highly neuroattenuated, and when used in different mouse models of various nervous system-derived tumor types, showed slowed tumor growth and prolonged survival. However, clinical trials were not pursued (i) because of undesirable level of toxicity at high titers, and (ii) because its tk-negative status made it resistant to traditional antiherpetic treatments, a major disadvantage should any viral toxicity arise in treated patients. 22, 23 ICP6 mutants have been tested as replicative anticancer agents, alone or in combination with acyclovir/ gancyclovir, as the mutants retain their sensitivity to such antivirals. Moreover, the RR À mutants have been shown to display an increased sensitivity to gancyclovir, compared to the wt virus. These recombinant viruses showed enhanced killing of tumor cells in vitro, and showed improved survival of animals. However, like TK mutants, they can cause fatal encephalitis when used at sufficient doses and were not thought to provide a sufficient margin of safety for testing in humans. 24, 25 It has been shown that deletion of ICP34.5, the neurovirulence factor essential for HSV pathogenicity, provides the greatest degree of attenuation of any individual mutation where the virus can still replicate in actively dividing cells. R3616, the prototype HSV-1 deleted in both copies of g34.5, had demonstrated attenuated neurovirulence but with maintained antiglioma activity, and was found to produce no encephalitis in a nude mouse model. [26] [27] [28] The use of g34.5 mutated viruses demonstrated considerable antitumor efficacy, combined with a good safety profile, and different versions of HSV ICP34.5-deleted are currently in human clinical trials. 29 Following preclinical testing with the above-mentioned oncolytic vectors, second-generation vectors with multigenic mutations were created. G207 contains deletion in both g34.5 loci and a lac-Z gene insertion in the ICP6 gene. 30 These multiple mutations made the reversion to wt highly unlikely and conferred several important safety advantages. Moreover, G207 retains its susceptibility to standard anti-HSV therapies such as 31 The data obtained in the previous experiment allowed the move into Phase I clinical trials, 32 and, presently, enrollment has begun for sequential Phases Ib/II trials employing G207 as an antitumor agent for malignant gliomas.
Almost simultaneously, HSV1716, derived from the parent wt strain HSV-1 17+ in which both the copies of g34.5 had been deleted, also underwent clinical trials to evaluate its toxicity in patients with recurrent human glioma, [33] [34] [35] after it was demonstrated to be avirulent in mice. 36 Oncolytic herpesviruses have been also studied as an oncolytic antitumor therapy against a variety of tumors different from GBM and anaplastic astrocytoma, such as human breast cancer in a brain metastatic model, 37 colorectal cancer and liver metastases, 38 prostate cancer, 39 pancreatic cancer, 40 and head and neck squamous carcinoma. 41 In many of these studies, the efficacy of G207 has been compared with that of the above mentioned NV1020, which was shown to be too attenuated to work as a live viral vaccine. 12, 13 Moreover, NV1020 is currently being investigated in Phase I clinical trials for patients with colon cancer that has metastasized to the liver and has proven recalcitrant to chemotherapy. This is also the first trial to investigate administration via intravascular delivery. In fact, oncolytic viruses can be administered locally, by direct intratumoral inoculation, or systemically, by intravascular administration. However, the route of administration of the virus did influence efficacy, as was observed in the animal model.
Despite the promising results obtained with the engineered HSV-1-based oncolytic vectors described above, it is likely that a multimodal approach to eradicate cancer will be more effective with the final goal to improve safety and efficacy of the system. In this regard, oncolytic HSV vectors have been further modified to augment their antitumor efficacy, by incorporation of expression cassettes for the delivery of various transgenes. Moreover, if the therapeutic gene is chosen carefully, this may be synergistic with the antitumor effect of virus replication.
Molecules, including a number of interleukins and interferons, have been tested with oncolytic HSVs. Among these are IL-4, 42 IL-12, [43] [44] [45] IL-10, 42 GM-CSF, 20, 29, 45 and B7.1, 46 which increase tumor immune recognition. This approach also reduces the possibility of toxicity derived from the systemic administration of the cytokine.
Oncolytic HSVs have been tested, which encode different prodrug-activating systems other than endogenous TK activity of the virus. The 5-fluorocytosine (5-FC) prodrug/yeast cytosine deaminase (CD) gene system, 47 alone or in combination with the TK/gancyclovir system, 48, 49 and the cytocrome P-450/cyclophosphamide (CPA) system, 50, 51 were shown to induce beneficial effects.
Nevertheless, ICP34.5 mutants replicate with considerably reduced efficiency in most tumor cells, compared to wt HSV. To improve tumor-selective replication, an ICP34.5-deleted HSV with enhanced growth characteristics was isolated after serial passages on a tumor cell line. This mutant was also found to give improved antitumor activity in vivo, without compromising safety. 52 These improved characteristics were found to derive from a second site suppressor mutation in the unique short region, which determines the expression of the US11 gene as an IE rather than an L gene, and the deletion of US12, encoding the ICP47 protein, contributing the improvement of antitumor immune response. 53 This viral isolate was shown to exhibit enhanced antitumor effect. 21, 54 Most of the oncolytic HSVs analyzed have been based on serially passaged laboratory strains of HSV. These strains have probably lost some of their aggressive properties. It has in fact been recently demonstrated that an oncolytic HSV, JS1/ICP34.5-/ICP47-/GM-CSF, derived from a clinical isolate of HSV-1, possesses a higher ability to kill tumor cells in vitro and in vivo. Moreover, in a model of mouse lymphoma, mice cured with this virus were protected against further tumor challenge. 29 In early clinical trials, however, treatment with the current generation of oncolytic viruses did not significantly affect tumor growth. 32, 35 This suboptimal result may reflect viral gene deletions, which can reduce the replicative potential of viruses in tumor cells. For example, deletion of the g34.5 gene significantly reduced viral growth even in rapidly dividing cells. 21, 24, 42 A variety of strategies are being pursued to enhance the potency of oncolytic viruses. Overall, the results so far obtained demonstrate that incorporating suicide and/or cytokine transgenes in the viral genome can increase antitumor efficacy, especially if used in combination with pre-existing anticancer treatments such as chemotherapy or radiotherapy. 7, 51, 55, 56 Another strategy is to clone therapeutic genes into the viral genome to arm the virus with additional cytotoxic mechanisms that augment the direct lytic functions of the virus. Particularly attractive in this context are cytotoxic mechanisms with potent bystander effect capable of eliminating tumor cells that the virus cannot reach. To this purpose, it has been recently demonstrated that incorporation of cell membrane fusion capability into an oncolytic HSV can significantly increase the antitumor potency of the virus. [57] [58] [59] These oncolytic HSVs were constructed by three different methods: (i) screening for the syncytial phenotype after random mutation of a well-established oncolytic HSV (to obtain Fu-10); (ii) insertion of the gene encoding the hyperfusogenic membrane glycoprotein of gibbon ape leukemia virus (GALV.fus) into the genome of an oncolytic HSV (to generate Synco-2); and (iii) incorporation of both of these membrane fusion mechanisms into a single oncolytic HSV (to generate Synco-2D).
These vectors have been tested for their antitumor activity against liver, breast, ovarian and metastatic prostate cancers, showing a significant increase in viral oncolysis; this may lead to enhanced clinical performance, especially in late-stage cancer patients.
Targeting HSV attenuated vectors
To prevent damage of healthy tissues, to decrease the risk of germ line transduction, and to design vectors that can be administered intravenously, it is necessary to achieve targeted gene therapy. Genetic modifications to the genome of HSV-1 vectors have been generated to Replication-competent HSV vectors R Argnani et al preferentially target viral infection and/or replication to tumor cells versus normal cells. 17 Targeting viral infection to particular cells can be obtained by modifying the first steps of the virus life cycle, that is, adsorption and penetration. Efforts for engineering the HSV-1 envelope to obtain targeted infection are currently in progress. Altering HSV-1 host range has proved a formidable task because HSV-1 infection is a complex process involving the action of several glycoproteins in cell attachment, entry, and cell-to-cell spread ( Figure 2) .
As a first step, to eliminate the HSV tropism, a mutant virus deleted for gC and the HS binding domain of gB, namely KgBpK À gC À , was generated. 60 This virus was further engineered to redirect infection to erythropoietin (EPO)-receptor-positive cells using gC-EPO fusion molecules. It was demonstrated that one of the gC-EPO fusion molecules was incorporated into a recombinant HSV-1 viral envelope and was able to stimulate proliferation of EPO growth-dependent cell line FD-EPO. Otherwise, the lack of productive infection due to endocytosis of the virus resulted in an aborted infection. 61 It was recently demonstrated that the KgBpK À gC À virus, further modified to express and incorporate a fusion protein between gC and the preS1 active peptide (preS1ap) of HBV, was able to bind preferentially to hepatocytes, giving a productive infection. 62 However, this mutant still retains gD-binding functions. Simultaneously, efforts are in progress to modify gD, the other glycoprotein involved in HSV-1 binding and penetration into the host cell. 63, 64 In a recent report, the R5111 mutant virus was described lacking the HS binding domains of gB, and in which the HS and HVEM-binding regions of gC and gD were substituted with IL13-coding sequences. HSV-1 R5111 can infect J13R cells containing the IL13Ra2 receptor and lacking all other HSV-1 receptors. However, this mutant still retains the other gD-binding affinities, and it is not yet established whether it can productively infect the target cells, in a similar way to that obtained with wt HSV. 64 An alternative approach reports a transiently vesicular stomatitis virus glycoprotein G (VSV-G) pseudotyped gD minus HSV-1, but to date a stable mutant has not been reported. 63 A further stimulus to the search of new strategies to alter HSV cell tropism derives from a recent observation that selected mutations in gD can reduce or abolish entry/fusion activity with nectin-1 and nectin-2, the principal receptors for HSV-1 entry into neurons, without preventing the activity of HVEM or 3-0-S HS that alternatively, can mediate entry into T cells and fibroblasts. 65 These data suggest that strains carrying gD mutations may establish transient infections in humans, but perhaps not latent infections of neurons, and are therefore candidates for development of safe virus vaccine and vaccines vectors.
One strategy to target replication of the attenuated virus is obtained by eliminating viral functions necessary for replication in normal cells. These mutations give the virus the attenuated phenotype that leads to replication only in permissive cells such as dividing tumor cells or cells with defects in specific cancer pathways. 13, 23, 30, 66 However, a limitation of this strategy is that many normal tissues also have high mitotic indices, and such viruses may not discriminate between rapidly proliferating normal and cancer cells.
A second strategy to target viral replication to tumor cells consists in placing the expression of essential viral genes under the control of tumor or tissue-specific promoters that are preferentially active in tumor cells. [67] [68] [69] [70] The use of tissue-specific promoters to direct viral replication to a specific tumor type have been explored more extensively in oncolytic adenoviruses and use of these promoters to regulate HSV replication could be further explored. A limitation in the use of these promoters is that viral replication is mainly targeted at a specific tumor type and is often further restricted to only a subgroup. To this purpose, promoters active in most tumors 7, 70, 71 or radiation-responsive promoters have been explored, 72, 73 but there are instances where these promoters might be active in normal cells, leading to toxicity. A further obstacle is that, in the context of a tumor, it is likely that these promoters will not be active in all tumor cells and that not all cells will be infected. As a result, a subset of tumor cells will have a selective growth advantage and survive, leading to tumor recurrence.
Attenuated HSV vectors for gene delivery to the peripheral nervous system
One of the potential target organs of replicationcompetent HSV vector applications, the peripheral nervous system (PNS) seems likely to promise the most Figure 2 HSV-1 entry into cells and targeting strategies. The initial contact of the virus with the cell is the binding to the heparan sulfate (HS) proteoglycans on the cell surface, mediated by gC and gB. Subsequently, gD binds to one of its cellular receptors, including HVEM, a member of the TNFreceptor family; nectin-1 or 2, two related members of the immunoglobulin superfamily; or sites generated in HS by the action of specific 3-Osulfotransferases. This last binding triggers the fusion between the cell membrane and the viral envelope, which requires the action of gB, gD and gH-gL, with subsequent release of the viral nucleocapsid and tegument into the cytoplasm. In the picture are shown the main targeting strategies, aimed at deletion of the HS and gD-binding domains of gB/gC and gD, respectively, and substitution with other molecules that display specific cellular affinities. 74 In the PNS, there are a number of potential applications for HSV replication-competent vectors capable of peripheral replication and axonal transport, including the stimulation of regrowth of damaged nerves, the study and treatment of various pain states, the protection of neurons from further degeneration in, for example, motor neuron disease, the study and treatment of various neuropathies, the study of neuronal development, and the screening of the relevance of genes implicated as being important in any of these processes by a gene delivery approach. Thus, viruses mutated in gC or TK, or RR have been extensively used, which, while being somewhat attenuated compared to wt virus, are also replication competent. The data obtained to date show the potential of such vectors for gene transfer. Attenuated vectors were in fact demonstrated to be highly efficient in driving proenkephalin A (PA) gene expression in dorsal root ganglia (DRG) 75 to deliver genes into monkey eyes, 76 and to the rodent visual system, 77 and to express active nerve growth factor beta subunit (b-NGF) in latently infected DRG. 78 
Conclusions
Although HSV vectors were initially conceived for gene delivery to the brain, the most promising potential applications at present are in the PNS and in oncology. The fact that various genetically modified HSVs, which are much less attenuated than the potential vector backbones, have already been administered to patients in trials for malignant glioma and potential vaccines, 32, 34, 35 should make it easier to obtain regulatory approval for clinical trials. However, a number of efficacy, safety and manufacturing issues need to be assessed before considering an HSV vector ready for clinical applications. A genetically stable vector is desirable from both the safety and manufacturing standpoints. Moreover, a genetic approach to preventing undesirable viral spreading is essential, and a secondary mechanism to inactivate the vector should ideally be available. Finally, the vector must be amenable to high titer production and purification under Good Manufacturing Practice (GMP) guidelines for clinical studies.
